Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Barrington Research Assumes Coverage On Opko Health On Positive Outlook

Share:

In a report published Thursday, Barrington Research analyst Michael Petusky assumed coverage on Opko Health, Inc. (NYSE: OPK) with an Outperform rating and $19.00 price target.

In the report, Barrington Research noted, "We are assuming coverage of OPKO Health due to an analyst transition. Headquartered in Miami, Florida OPKO primarily focuses on point-of-care diagnostics, novel molecular diagnostics, and pharmaceuticals...Led by long-time healthcare executive Phillip Frost, OPKO has many additional shots on goal even beyond the opportunities within its currently commercialized product portfolio and its front-burner pipeline products, Rayaldee, and hGH-CTP. We have included information on pages 2 and 3, which illustrates key aspects of the current product portfolio as well as the depth of the product pipeline."

Opko Health closed on Wednesday at $13.88.

Latest Ratings for OPK

DateFirmActionFromTo
Mar 2018DowngradesNeutralUnderweight
Sep 2017DowngradesOverweightNeutral
Aug 2017Initiates Coverage OnOverweight

View More Analyst Ratings for OPK
View the Latest Analyst Ratings

Posted-In: Barrington Research Michael PetuskyAnalyst Color Initiation Analyst Ratings

 

Related Articles (OPK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NUEMaintains61.0
MMCMaintains105.0
BTIDowngrades
DGMaintains142.0
MDLZMaintains52.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Is Goldman Sachs A Better Bet Than Morgan Stanley? Credit Suisse Thinks So

B Riley Downgrades Coty To Sell